GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Garden Biopharmaceutical Co Ltd (SZSE:300401) » Definitions » Return-on-Tangible-Asset

Zhejiang Garden Biopharmaceutical Co (SZSE:300401) Return-on-Tangible-Asset : 7.21% (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Zhejiang Garden Biopharmaceutical Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Zhejiang Garden Biopharmaceutical Co's annualized Net Income for the quarter that ended in Mar. 2025 was ¥386 Mil. Zhejiang Garden Biopharmaceutical Co's average total tangible assets for the quarter that ended in Mar. 2025 was ¥5,351 Mil. Therefore, Zhejiang Garden Biopharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was 7.21%.

The historical rank and industry rank for Zhejiang Garden Biopharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:

SZSE:300401' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.65   Med: 10.24   Max: 22.11
Current: 5.9

During the past 13 years, Zhejiang Garden Biopharmaceutical Co's highest Return-on-Tangible-Asset was 22.11%. The lowest was 1.65%. And the median was 10.24%.

SZSE:300401's Return-on-Tangible-Asset is ranked better than
66.41% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.625 vs SZSE:300401: 5.90

Zhejiang Garden Biopharmaceutical Co Return-on-Tangible-Asset Historical Data

The historical data trend for Zhejiang Garden Biopharmaceutical Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Garden Biopharmaceutical Co Return-on-Tangible-Asset Chart

Zhejiang Garden Biopharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.95 14.38 10.53 4.27 5.91

Zhejiang Garden Biopharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.05 3.83 7.51 5.05 7.21

Competitive Comparison of Zhejiang Garden Biopharmaceutical Co's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Garden Biopharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Garden Biopharmaceutical Co's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Garden Biopharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Zhejiang Garden Biopharmaceutical Co's Return-on-Tangible-Asset falls into.


;
;

Zhejiang Garden Biopharmaceutical Co Return-on-Tangible-Asset Calculation

Zhejiang Garden Biopharmaceutical Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=309.213/( (5063.847+5403.399)/ 2 )
=309.213/5233.623
=5.91 %

Zhejiang Garden Biopharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=386.044/( (5403.399+5297.824)/ 2 )
=386.044/5350.6115
=7.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Zhejiang Garden Biopharmaceutical Co  (SZSE:300401) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Zhejiang Garden Biopharmaceutical Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Zhejiang Garden Biopharmaceutical Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Garden Biopharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 166, Street 20, Economic & Technological Development Zone, Zhejiang, Hangzhou, CHN, 310018
Zhejiang Garden Biopharmaceutical Co Ltd is a China-based company. Along with its subsidiaries, the firm is engaged in the pharmaceutical manufacturing. Its business activities include research, production, and sale of vitamin D3, cholesterol, and lanolin products. Its products include lanolin alcohol pharma, lanolin alcohol cosmetic, cholesterol BP, vitamin D3 oil feed grade, vitamin D3 500 feed grade CWS, lanolin alcohol EP 200, among others.
Executives
Shao Xu Jun Director
Liu Xiao Ping Executives
Shao Qin Xiang Director
Shao Jun Fang Director
Liu Jian Gang Directors, executives
Qian Guo Ping Executives
Zhu Jian Xing Supervisors
Yu Quan Heng Directors, executives, directors
Ma Huan Zheng Directors, executives
Li Hui Ying Supervisors
Ma Wen De Director
Chen Yi Executives
Gu Yi Kang Independent director

Zhejiang Garden Biopharmaceutical Co Headlines

No Headlines